CD38 and plasma cell myeloma: To address these questions, here, we have taken advantage of CRISPR interference (CRISPRi)–based functional genomic screens, cell surface proteomics, epigenetic analyses, and phosphoproteomics to provide a multiomic perspective on CD38 regulation and tumor cell consequences of targeting CD38 in myeloma.